Incidence and mortality due to cervical cancer in 4 south European countries

Abstract

Objective:To describe variation in incidence and mortality rates of cervical cancer (CC), between 4 Southern European countries that share similar cultural characteristics.Methods:Data on CC incidence and mortality reported in Portugal, Spain, Italy, and Greece for the year 2012 were obtained through the International Agency of Research on Cancer. Expected numbers of incident cases and deaths were obtained based on age-specific rates in European region. Standardized incidence rate (SIR) and standardized mortality rate (SMR) and respective 95% confidence interval (95% CI) were computed for each country by age group (15–39, 40–54, 55–64, and ≥65 years old).Results:The number of incident cases of and deaths due to CC observed in Greece, Italy, and Spain were significantly lower than expected, whichever the age group. In Portugal such pattern was, however, only found for incident cases among women aged up to 54 years. The number of incident cases observed in Portugal did not differ from that expected among women aged 55 to 64 (SIR = 90.8; 95% CI: 76.8–106.7) and aged 65 or more years (SIR = 110.0; 95% CI: 95.9–125.0). Also, the number of deaths observed in Portugal did not differ from that expected among women aged 15 to 39 (SMR = 70.0; 95% CI: 43.3–100.8), 40 to 54 (SMR = 93.6; 95% CI: 74.9–115.4), and 55 to 64 years (SMR = 93.6; 95% CI: 73.4–117.7) but was significantly higher than that expected among women aged 65 or more years (SMR = 126.7; 95% CI: 110.1–144.4).Conclusions:There is variability in CC incidence and mortality between 4 South European countries. To understand the reasons underlying such variability could improve approach to preventive care.

The Effects of Age, Period, and Cohort on the Mortality of Cervical Cancer in Three High‐Income Countries: Canada, Korea, and Italy

“…More than 60,000 females are newly diagnosed with cervical cancer and over 25,000 women die from the disease every year in Europe, and cervical cancer is estimated to be one of the top 10 leading causes of cancer death in some Asian countries [ 6 , 7 ]. While widespread cytology screening has dramatically reduced the morbidity and mortality of cervical cancer in many developed countries, it remains a significant health risk with relatively high burden of disease among European and Asian female populations, particularly affecting young women [ 8 – 10 ].…”

Bazedoxifene, a GP130 Inhibitor, Modulates EMT Signaling and Exhibits Antitumor Effects in HPV-Positive Cervical Cancer

“…According to the International Agency for Research on global cancer estimation, there were 569,847 new cervical cases and 311,365 deaths worldwide in 2018, accounting for 3.2% of new female cancer cases and deaths [4]. Although extensive cytological examination has dramatically reduced the morbidity and mortality of cervical cancer in many developed countries, it still remains a serious health risk [5].…”